英国剑桥博士后研究员 - 临床前纳米药物药理学

We're currently looking for talented scientists to join our innovative academic-style Postdoc. From our centre in Cambridge UK, you'll be in a global pharmaceutical environment, contributing to live projects right from the start. You'll take part in a comprehensive training programme, including a focus on drug discovery and development, given access to our existing Postdoctoral research, and encourag ed to pursue your own independent research in cutting edge laboratories. It's a newly expanding programme spanning a range of therapeutic areas across a wide range of disciplines.

What's more, you'll have the support of a leading academic advisor, who'll provide you with the guidance and knowledge you need to develop your career. This is an exciting area that hasn't been explored to its full potential, making this an opportunity to make a real difference to the future of medical science.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines for some of the world's most serious diseases. But we're more than one of the world's leading pharmaceutical companies. At AstraZeneca, we're proud to have a unique workplace culture that inspires innovation and collaboration. Here, employees are empowered to express diverse perspectives – and are made to feel valued, energised and rewarded for their ideas and creativity.

Pharmaceutical Sciences IMEDis a global organisation that is responsible for engineering delivery systems for therapeutics. This ranges from familiar technologies like pills and solutions, to more advanced preparations for inhalation and nanomedical applications.

This is an exciting opportunity for you to break new ground in a scientific area which is of critical importance to AstraZeneca's future drug portfolio. Nucleic acid-based therapeutics, like messenger RNA and antisense oligonucleotides, are new therapeutic modalities of strategic importance to AstraZeneca. These modalities have the potential to transform the way we treat disease but their successful therapeutic application is currently limited by inefficient intracellular delivery. The iterative developme nt of new formulations for nucleic acid delivery requires extensive in vivo assessment due to a lack of predictive in vitro models. Performing in vivo assessment is limited by inadequate tools to quantitatively assess pharmacokinetic and pharmacodynamic effects of delivery systems and their cargos. Furthermore in vivo studies are resource intensive and low throughput. The aim of this project is to address these challenges focusing on the following areas:

Investigation of novel tools for assessment of the in vivo biodistribution of delivery systems and their cargos on a cellular, tissue and organ level. Developing barcoding methodologies which will allow high throughput in vivo assessment of delivery systems. Applying new in vivo methodologies for iterative screening of novel formulations for nucleic acid delivery. You will be embedded in a multidisciplinary team that will present you with the op portunity to learn from considerable internal expertise across exciting technologies including IVIS imaging, mass spectrometry imaging and high content biology. You will also be exposed to experts working on developing cutting-edge drug delivery technologies. This breadth and depth of expertise will support you in producing high impact work that you will publish and present to the external international scientific community.

Essential

• Ph.D. degree or equivalent qualification with specialisation in pharmacology, pharmaceutics or equivalent scientific discipline
• Experience working with mouse-based in vivo models
• Experience in cell culture and basic molecular biology techniques.
• Strong knowledge of approaches for assessing pharmacology of nucleic acids (e.g. mRNA, ASOs) and associated carriers (e.g. L NPs, polymers)
• Good knowledge of physiological barriers associated with delivery of nanomedicines, with specific understanding of the key mechanisms/pathways and challenges involved in the intracellular delivery of nucleic acids
• Proven ability to drive innovative research though internalisation of new techniques and technology, problem solving experience, as well as forming internal and external collaborations.
• Track record of scientific excellence, with a strong publication record and engagement with the scientific community through both conferences and collaborations.

Desirable

• Experience working with mouse based in vivo tumour models
• Strong expertise in a range of dosing routes for parenteral drug delivery
• Experience with in vivo imaging/detection pl atforms
• Knowledge of nanomedicine delivery technologies for nucleic acids e.g. LNPs, polymers
• Strong publication record in the field of nanomedicine

This is a 3 year programme – 2 years will be a Fixed Term Contract, with a 1 year extension which will be merit based. The role will be based in Cambridge, UK with a competitive salary on offer. To apply for this position, please click the apply link below. Advert Opening Date 20th February 2018 / Advert Closing Date 25th March 2018

AstraZeneca welcomes applications from all sections of the community – An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, colour, religion, sex, national origin, or protected veter an status and will not be discriminated against on the basis of disability.